Latest from UC Davis

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma.
Advances in treatment and supportive care have resulted in substantial improvements in cancer survival and a growing number of cancer survivors in the United States.
David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the Lung Master Protocol (Lung-MAP) Trial and how it is an example of a rational clinical design that will impact patient care. Gandara shared this insight during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.
David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the most recent—and significant—advancements in the field of lung cancer.
Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of the phase Ib JAVELIN Solid Tumor Trial.
Researchers at the UC Davis Comprehensive Cancer Center are personalizing treatment using tumor xenografts in mice to test and identify more precise treatments for bladder cancer patients.
NCI-designated cancer centers are tasked with moving the field forward. It's a responsibility that everyone at UC Davis Comprehensive Cancer Center takes seriously.
Clinical trial designs are transforming dramatically in order to expedite the discovery and validation of new predictive biomarkers for patients with non–small cell lung cancer and other types of solid tumors.
Publication Bottom Border
Border Publication
x